Show simple item record

dc.contributor.authorOnsøien, Mari Olsen
dc.contributor.authorMidtvedt, Karsten
dc.contributor.authorReisæter, Anna Varberg
dc.contributor.authorAasarød, Knut
dc.contributor.authorWaldum-Grevbo, Bård
dc.contributor.authorVikse, Bjørn Egil
dc.contributor.authorEriksen, Bjørn Odvar
dc.contributor.authorÅsberg, Anders
dc.date.accessioned2021-07-13T09:24:29Z
dc.date.available2021-07-13T09:24:29Z
dc.date.issued2021-03-25
dc.description.abstract<i>Background</i> - Hypertension in kidney transplant (KTx) recipients is common, affecting both patient and graft survival. Annual data from the Norwegian Renal Registry reveal that <50% of adult (>18 y) KTx recipients reach target blood pressure (BP) ≤130/80 mm Hg. The aim of this study was to identify the determinants of failure to achieve BP control.<br><br> <i>Methods</i> - In conjunction with the 2018 annual data reporting, additional questions were added for recipients with BP >130/80 mm Hg (treating physician´s target BP for each patient, reasons for not achieving target, method of measurement).<br><br> <i>Results</i> - Annual forms were received from 98% (3407 of 3486) of KTx recipients, with 1787 (52%) reporting a BP >130/80 mm Hg (“above-target” group). These recipients were older, mostly male, with higher body mass index and serum creatinine levels (<i>P</i> < 0.05) compared with patients with controlled hypertension (“on-target” group). Valid survey answers were available for 84% of the “above-target” group (Surv<sub>resp</sub>) with no significant demographic differences versus nonresponders (Surv<sub>nonresp</sub>). Among Surv<sub>resp,</sub> 32% were under antihypertensive dose titration, whereas dose-limiting side effects were reported in 7%. Target BP was confirmed to 130/80 mm Hg for 60% of Surv<sub>resp.</sub> In recipients for whom the treating physician set target BP >130/80 mm Hg, 51% did not reach these individual targets. The number of antihypertensive drugs was significantly higher in the “above-target” group versus “on-target” group (mean 2.1 ± 1.2 versus 1.8 ± 1.3) and 36% versus 25% used ≥3 antihypertensive drugs (<i>P</i> < 0.05). Automatic attended BP measurement was utilized by 51%.<br><br> <i>Conclusions</i> - In KTx recipients, a higher BP target achievement seems possible, potentially in the range of 75%-80%.en_US
dc.identifier.citationOnsøien, Midtvedt K, Reisæter AV, Aasarød K, Waldum-Grevbo B, Vikse BE, Eriksen BO, Åsberg A. Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?. Transplantation direct. 2021;7(4):e688en_US
dc.identifier.cristinIDFRIDAID 1901924
dc.identifier.doi10.1097/TXD.0000000000001142
dc.identifier.issn2373-8731
dc.identifier.urihttps://hdl.handle.net/10037/21868
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.relation.journalTransplantation direct
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleBlood Pressure Treatment in Kidney Transplant Recipients - Can We Improve?en_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record